Asthma and chronic obstructive pulmonary disease overlap: Asthmatic chronic obstructive pulmonary disease or chronic obstructive asthma?

Therapeutic Advances in Respiratory Disease

Volumn 10, Issue 1, 2016, Pages 57-71

  Slats, Annelies ^a   Taube, Christian ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

asthma chronic obstructive pulmonary disease overlap syndrome; phenotype

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; BRONCHODILATING AGENT; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CORTICOSTEROID; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 13 ANTIBODY; INTERLEUKIN 17 ANTIBODY; INTERLEUKIN 5 ANTIBODY; MACROLIDE; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; TIOTROPIUM BROMIDE;

AIRFLOW; AIRWAY REMODELING; ASTHMA; ASTHMA CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; DISEASE EXACERBATION; EOSINOPHILIA; HUMAN; INFLAMMATION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT ALLERGY; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOKING; ANIMAL; MIDDLE AGED; NOMENCLATURE; PATHOPHYSIOLOGY; PHENOTYPE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ANIMALS; ASTHMA; HUMANS; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TERMINOLOGY AS TOPIC;

EID: 84957549467     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465815617082     Document Type: Review

References (102)

1. Anderson D., Macnee W., (2009) Targeted treatment in COPD: a multi-system approach for a multi-system disease. Int J Chron Obstruct Pulmon Dis 4: 321-335.
2. Anthonisen N., Connett J., Murray R., (2002) Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 166: 675-679.
3. Bafadhel M., McKenna S., Terry S., Mistry V., Reid C., Haldar P., et al. (2011) Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 184: 662-671.
4. Barnes P., (2015) Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol 136: 531-545.
5. Bastard J., Maachi M., Lagathu C., Kim M., Caron M., Vidal H., et al. (2006) Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 17: 4-12.
6. Betz R., Kohlhaufl M., Kassner G., Mullinger B., Maier K., Brand P., et al. (2001) Increased sputum IL-8 and IL-5 in asymptomatic nonspecific airway hyperresponsiveness. Lung 179: 119-133.
7. Bosken C., Wiggs B., Pare P., Hogg J., (1990) Small airway dimensions in smokers with obstruction to airflow. Am Rev Respir Dis 142: 563-570.
8. Boulet L., Lemiere C., Archambault F., Carrier G., Descary M., Deschesnes F., (2006) Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. Chest 129: 661-668.
9. Boulet L., Turcotte H., Turcot O., Chakir J., (2003) Airway inflammation in asthma with incomplete reversibility of airflow obstruction. Respir Med 97: 739-744.
10. Brightling C., McKenna S., Hargadon B., Birring S., Green R., Siva R., et al. (2005) Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax 60: 193-198.
11. Brightling C., Monteiro W., Ward R., Parker D., Morgan M., Wardlaw A., et al. (2000) Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 356: 1480-1485.
12. Brutsche M., Downs S., Schindler C., Gerbase M., Schwartz J., Frey M., et al. (2006) Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 61: 671-677.
13. Bumbacea D., Campbell D., Nguyen L., Carr D., Barnes P., Robinson D., et al. (2004) Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 24: 122-128.
14. Burge P., Calverley P., Jones P., Spencer S., Anderson J., Maslen T., (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320: 1297-1303.
15. Chalmers G., MacLeod K., Thomson L., Little S., McSharry C., Thomson N., (2001) Smoking and airway inflammation in patients with mild asthma. Chest 120: 1917-1922.
16. Christenson S., Steiling K., van den Berge M., Hijazi K., Hiemstra P., Postma D., et al. (2015) Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 191: 758-766.
17. Chung J., Kong K., Lee J., Lee S., Ryu Y., Chang J., (2014) Characteristics and self-rated health of overlap syndrome. Int J Chron Obstruct Pulmon Dis 9: 795-804.
18. Contoli M., Baraldo S., Marku B., Casolari P., Marwick J., Turato G., et al. (2010) Fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease: 5-year follow-up. J Allergy Clin Immunol 125: 830-837.
19. Dahl M., Vestbo J., Lange P., Bojesen S., Tybjaerg-Hansen A., Nordestgaard B., (2007) C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: 250-255.
20. Danesh J., Wheeler J., Hirschfield G., Eda S., Eiriksdottir G., Rumley A., et al. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350: 1387-1397.
21. Davies L., Angus R., Calverley P., (1999) Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 354: 456-460.
22. De Marco R., Accordini S., Cerveri I., Corsico A., Anto J., Kunzli N., et al. (2007) Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 175: 32-39.
23. De Marco R., Pesce G., Marcon A., Accordini S., Antonicelli L., Bugiani M., et al. (2013) The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One 8: e62985.
24. De Martinis M., Franceschi C., Monti D., Ginaldi L., (2005) Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 579: 2035-2039.
25. Diaz-Guzman E., Khosravi M., Mannino D., (2011) Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population. COPD 8: 400-407.
26. Dickens J., Miller B., Edwards L., Silverman E., Lomas D., Tal-Singer R., (2011) COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res 12: 146.
27. Disantostefano R., Li H., Rubin D., Stempel D., (2013) Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open 3: e001838.
28. Domingo-Salvany A., Lamarca R., Ferrer M., Garcia-Aymerich J., Alonso J., Felez M., et al. (2002) Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166: 680-685.
29. Fabbri L., Romagnoli M., Corbetta L., Casoni G., Busljetic K., Turato G., et al. (2003) Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167: 418-424.
30. Fletcher C., Peto R., (1977) The natural history of chronic airflow obstruction. Br Med J 1: 1645-1648.
31. Fu J., McDonald V., Gibson P., Simpson J., (2014) Systemic Inflammation in older adults with asthma-COPD overlap syndrome. Allergy Asthma Immunol Res 6: 316-324.
32. Gelb A., Nadel J., (2015) Understanding the pathophysiology of the asthma-chronic obstructive pulmonary disease overlap syndrome. J Allergy Clin Immunol 136: 553-555.
33. Ghebre M., Bafadhel M., Desai D., Cohen S., Newbold P., Rapley L., et al. (2015) Biological clustering supports both 'Dutch' and 'British' hypotheses of asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol 135: 63-72.
34. Gibson P., Simpson J., (2009) The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 64: 728-735.
35. GINA-GOLD (2015) Asthma, COPD and asthma-COPD overlap syndrome (ACOS). Available at: http://www.goldcopd.org/asthma-copd-overlap.html (. accessed 5 August 2015).
36. Glaab T., Taube C., (2011) Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease. Pulm Pharmacol Ther 24: 15-22.
37. Global Initiative for Asthma (GINA) (2015) Global strategy for asthma management and prevention. Available at: http://www.ginasthma.org/ (. accessed 12 August 2015).
38. Global Initiative for Chronic Obstructive Lung Disease (GOLD) (2015) Global strategy for the diagnosis, management and prevention of COPD. Available at: http://www.goldcopd.org/ (. accessed 12 August 2015).
39. Golpe R., Sanjuan L., Cano J., Castro A., Perez de Llano L., (2014) Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke. Arch Bronconeumol 50: 318-324.
40. Green R., Brightling C., McKenna S., Hargadon B., Parker D., Bradding P., et al. (2002) Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360: 1715-1721.
41. Hardin M., Cho M., McDonald M., Beaty T., Ramsdell J., Bhatt S., et al. (2014) The clinical and genetic features of COPD-asthma overlap syndrome. Eur Respir J 44: 341-350.
42. Hardin M., Silverman E., Barr R., Hansel N., Schroeder J., Make B., et al. (2011) The clinical features of the overlap between COPD and asthma. Respir Res 12: 127.
43. Hogg J., Chu F., Utokaparch S., Woods R., Elliott W., Buzatu L., et al. (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350: 2645-2653.
44. Hospers J., Schouten J., Weiss S., Rijcken B., Postma D., (1999) Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. Am J Respir Crit Care Med 160: 1869-1874.
45. Iwamoto H., Gao J., Koskela J., Kinnula V., Kobayashi H., Laitinen T., et al. (2014) Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. Eur Respir J 43: 421-429.
46. Izquierdo-Alonso J., Rodriguez-Gonzalezmoro J., de Lucas-Ramos P., Unzueta I., Ribera X., Anton E., et al. (2013) Prevalence and characteristics of three clinical phenotypes of chronic obstructive pulmonary disease (COPD). Respir Med 107: 724-731.
47. James A., Palmer L., Kicic E., Maxwell P., Lagan S., Ryan G., et al. (2005) Decline in lung function in the Busselton Health Study: the effects of asthma and cigarette smoking. Am J Respir Crit Care Med 171: 109-114.
48. James A., Wenzel S., (2007) Clinical relevance of airway remodelling in airway diseases. Eur Respir J 30: 134-155.
49. Karlsen J., Borregaard N., Cowland J., (2010) Induction of neutrophil gelatinase-associated lipocalin expression by co-stimulation with interleukin-17 and tumor necrosis factor-alpha is controlled by IkappaB-zeta but neither by C/EBP-beta nor C/EBP-delta. J Biol Chem 285: 14088-14100.
50. Kauppi P., Kupiainen H., Lindqvist A., Tammilehto L., Kilpelainen M., Kinnula V., et al. (2011) Overlap syndrome of asthma and COPD predicts low quality of life. J Asthma 48: 279-285.
51. Kerstjens H., Overbeek S., Schouten J., Brand P., Postma D., (1993) Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. Eur Respir J 6: 868-876.
52. Kitaguchi Y., Komatsu Y., Fujimoto K., Hanaoka M., Kubo K., (2012) Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis 7: 283-289.
53. Kottyan L., Collier A., Cao K., Niese K., Hedgebeth M., Radu C., et al. (2009) Eosinophil viability is increased by acidic pH in a cAMP- and GPR65-dependent manner. Blood 114: 2774-2782.
54. Lange P., Parner J., Vestbo J., Schnohr P., Jensen G., (1998) A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 339: 1194-1200.
55. Lazarus S., Chinchilli V., Rollings N., Boushey H., Cherniack R., Craig T., et al. (2007) Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 175: 783-790.
56. Leckie M., ten Brinke A., Khan J., Diamant Z., O'Connor B., Walls C., et al. (2000) Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144-2148.
57. Lee H., Kang J., Yoon H., Lee S., Kwon S., Kim Y., et al. (2014) Clinical characteristics of asthma combined with COPD feature. Yonsei Med J 55: 980-986.
58. Leigh R., Pizzichini M., Morris M., Maltais F., Hargreave F., Pizzichini E., (2006) Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 27: 964-971.
59. Louie S., Zeki A., Schivo M., Chan A., Yoneda K., Avdalovic M., et al. (2013) The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol 6: 197-219.
60. Magnussen H., Bugnas B., van Noord J., Schmidt P., Gerken F., Kesten S., (2008) Improvements with tiotropium in COPD patients with concomitant asthma. Respir Med 102: 50-56.
61. Marsh S., Travers J., Weatherall M., Williams M., Aldington S., Shirtcliffe P., et al. (2008) Proportional classifications of COPD phenotypes. Thorax 63: 761-767.
62. McDonald V., Higgins I., Wood L., Gibson P., (2013) Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense? Thorax 68: 691-694.
63. McDonough J., Yuan R., Suzuki M., Seyednejad N., Elliott W., Sanchez P., et al. (2011) Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 365: 1567-1575.
64. Menezes A., Montes de, Oca M., Perez-Padilla R., Nadeau G., Wehrmeister F., Lopez-Varela M., et al. (2014) Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest 145: 297-304.
65. Miravitlles M., (2011) Arguments in favor of inhaled corticosteroids in COPD by phenotype instead of by severity. Arch Bronconeumol 47: 271-273.
66. Miravitlles M., Huerta A., Fernandez-Villar J., Alcazar B., Villa G., Forne C., et al. (2014a) Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems. Health Qual Life Outcomes 12: 120.
67. Miravitlles M., Soler-Cataluna J., Calle M., Molina J., Almagro P., Quintano J., et al. (2014b) Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol 50 (Suppl. 1): 1-16.
68. Miravitlles M., Soriano J., Ancochea J., Munoz L., Duran-Tauleria E., Sanchez G., et al. (2013) Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med 107: 1053-1060.
69. Nakawah M., Hawkins C., Barbandi F., (2013) Asthma, chronic obstructive pulmonary disease (COPD), and the overlap syndrome. J Am Board Fam Med 26: 470-477.
70. O'Donnell D., Aaron S., Bourbeau J., Hernandez P., Marciniuk D., Balter M., et al. (2007) Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J 14 (Suppl. B): 5B-32B.
71. Orie N. G. M., Sluiter H. J., De Vries K., Tammeling G. J., Witkop J., (1961) The host factor in bronchitis. In: Orie N. G. M., Sluiter HJ, (eds) Bronchitis. Assen, The Netherlands: Royal Van Gorcum, 1961. pp. 43-59.
72. Paggiaro P., Dahle R., Bakran I., Frith L., Hollingworth K., Efthimiou J., (1998) Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 351: 773-780.
73. Panizza J., James A., Ryan G., de Klerk N., Finucane K., (2006) Mortality and airflow obstruction in asthma: a 17-year follow-up study. Intern Med J 36: 773-780.
74. Papi A., Romagnoli M., Baraldo S., Braccioni F., Guzzinati I., Saetta M., et al. (2000) Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 162: 1773-1777.
75. Peat J., Woolcock A., Cullen K., (1987) Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 70: 171-179.
76. Perret J., Dharmage S., Matheson M., Johns D., Gurrin L., Burgess J., et al. (2013) The interplay between the effects of lifetime asthma, smoking, and atopy on fixed airflow obstruction in middle age. Am J Respir Crit Care Med 187: 42-48.
77. Pinto-Plata V., Mullerova H., Toso J., Feudjo-Tepie M., Soriano J., Vessey R., et al. (2006) C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 61: 23-28.
78. Postma D., Rabe K., (2015) The asthma-COPD overlap syndrome. N Engl J Med 373: 1241-1249.
79. Reddel H., (2015) Treatment of overlapping asthma-chronic obstructive pulmonary disease: can guidelines contribute in an evidence-free zone? J Allergy Clin Immunol 136: 546-552.
80. Rhee C., Yoon H., Yoo K., Kim Y., Lee S., Park Y., et al. (2014) Medical utilization and cost in patients with overlap syndrome of chronic obstructive pulmonary disease and asthma. COPD 11: 163-170.
81. Rijcken B., Schouten J., Mensinga T., Weiss S., De Vries K., Van der Lende R., (1993) Factors associated with bronchial responsiveness to histamine in a population sample of adults. Am Rev Respir Dis 147: 1447-1453.
82. Shaw D., Berry M., Hargadon B., McKenna S., Shelley M., Green R., et al. (2007) Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest 132: 1871-1875.
83. Simpson J., Baines K., Boyle M., Scott R., Gibson P., (2009) Oncostatin M (OSM) is increased in asthma with incompletely reversible airflow obstruction. Exp Lung Res 35: 781-794.
84. Siva R., Green R., Brightling C., Shelley M., Hargadon B., McKenna S., et al. (2007) Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 29: 906-913.
85. Skold C., (2010) Remodeling in asthma and COPD-differences and similarities. Clin Respir J 4 (Suppl. 1): 20-27.
86. Smolonska J., Koppelman G., Wijmenga C., Vonk J., Zanen P., Bruinenberg M., et al. (2014) Common genes underlying asthma and COPD? Genome-wide analysis on the Dutch hypothesis. Eur Respir J 44: 860-872.
87. Soler-Cataluna J., Cosio B., Izquierdo J., Lopez-Campos J., Marin J., Aguero R., et al. (2012) Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 48: 331-337.
88. Soriano J., Davis K., Coleman B., Visick G., Mannino D., Pride N., (2003) The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 124: 474-481.
89. Tashkin D., Altose M., Connett J., Kanner R., Lee W., Wise R., (1996) Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med 153: 1802-1811.
90. Telenga E., Kerstjens H., Postma D., Ten Hacken N., van den Berge M., (2010) Inhaled corticosteroids in chronic obstructive pulmonary disease: a review. Expert Opin Pharmacother 11: 405-421.
91. Ten Brinke A., Zwinderman A., Sterk P., Rabe K., Bel E., (2001) Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 164: 744-748.
92. Thomson N., Chaudhuri R., Livingston E., (2004) Asthma and cigarette smoking. Eur Respir J 24: 822-833.
93. Thorleifsson S., Margretardottir O., Gudmundsson G., Olafsson I., Benediktsdottir B., Janson C., et al. (2009) Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. Respir Med 103: 1548-1553.
94. Van De Ven M., Engels R., Sawyer S., (2009) Asthma-specific predictors of smoking onset in adolescents with asthma: a longitudinal study. J Pediatr Psychol 34: 118-128.
95. Vermeire P., Pride N., (1991) A 'splitting' look at chronic nonspecific lung disease (CNSLD): common features but diverse pathogenesis. Eur Respir J 4: 490-496.
96. Vonk J., Jongepier H., Panhuysen C., Schouten J., Bleecker E., Postma D., (2003) Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax 58: 322-327.
97. Walter R., Wilk J., Larson M., Vasan R., Keaney J. Jr, Lipinska I., et al. (2008) Systemic inflammation and COPD: the Framingham Heart Study. Chest 133: 19-25.
98. Wenzel S., Schwartz L., Langmack E., Halliday J., Trudeau J., Gibbs R., et al. (1999) Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 160: 1001-1008.
99. Wenzel S., Szefler S., Leung D., Sloan S., Rex M., Martin R., (1997) Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 156: 737-743.
100. Wright J., Lawson L., Pare P., Wiggs B., Kennedy S., Hogg J., (1983) Morphology of peripheral airways in current smokers and ex-smokers. Am Rev Respir Dis 127: 474-477.
101. Yan L., Borregaard N., Kjeldsen L., Moses M., (2001) The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276: 37258-37265.
102. Yanbaeva D., Dentener M., Spruit M., Houwing-Duistermaat J., Kotz D., Passos V., et al. (2009) IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: a case-control study. BMC Med Genet 10: 23.